uromems.comCrawled Oct 16, 2026
UroMems aims at revolutionizing the treatment of stress urinary incontinence with smart active implants, using the latest technological advances in the field of embedded systems and micro-technologies.
UroActive is an implant to treat SUI powered by a MyoElectroMechanical System (MEMS). It is placed around the urethral duct and designed for remote control based on patient activity, without manual adjustments.
The page lists UroMems conference presentations at AUA 2025, EAU 2025, and SUFU 2025, including one-year results from the first-in-human SOPHIA study of an artificial urinary sphincter.
The page lists journal publications on UroActive, including a 2026 human assessment, a 2025 cadaver urodynamic comparison with AMS800, and a 2024 RAM2 publication.
“Now, at 1 year, the 1-hour pad test has been done again, as it’s part of the protocol, and she suffered 4 g of incontinence on this test, opposed to 125 g at the beginning,” says Emmanuel Chartier-Kastler, MD, PhD.
UroMems announced that the first female patient implanted with UroActive met the six-month primary endpoint.
Sama brings operational expertise to UroMems as the company prepares pivotal clinical trials for UroActive, an implant to treat stress urinary incontinence.
BOARD OF DIRECTORS Board Members Board Observers
Celia Hart, PhD, represents Supernova Invest and has more than 20 years of experience in the chemical and biotechnology sector. She joined CEA Investissement, now Supernova Invest, in 2005 and is an Investment Director and Partner.
Dan Rose is Chairman of the Board at UroMems and has more than 25 years of experience in the medical device industry. He guides the company as it prepares for pivotal clinical trials and the commercial launch of UroActive.
UroMems focuses on designing, developing, and commercializing active implantable medical devices.
UroMems lists contact details for its France and United States offices, including addresses, phone numbers, and info@uromems.com.
UroMems is developing breakthrough, automated technology to treat stress urinary incontinence (SUI) providing an improved quality of life for women and men.
UroMems says UroActive is under development, with its properties, performance, and safety still under evaluation. It is not available for prescription, delivery, sale, or use by patients or health care professionals.
